Want to see ELDN full AI Analyst Report?
Top Page
Eledon Pharmaceuticals
(NASDAQ:ELDN)
Select Model
Select Model
Rating:42Neutral
Price Target:
$2.50
▼(-24.70% Downside)
Action:Reiterated
Date:09/30/26
The score is driven primarily by weak financial performance (no revenue, large and recently worsening losses, and sustained cash burn that increases financing/dilution risk). Technicals add further pressure with a clear downtrend below major moving averages and bearish MACD, despite oversold readings. Valuation offers limited support given the negative P/E and lack of dividend yield data.
Positive Factors
Very low leverage
Minimal debt reduces solvency risk and avoids a substantial interest burden while Eledon funds clinical development. This gives management greater flexibility to allocate capital toward tegoprubart and may provide more room to pursue financing or partnerships without an already heavily leveraged balance sheet.
Negative Factors
No reported revenue
Eledon has not yet demonstrated commercial revenue, so its operations remain dependent on advancing development programs rather than product sales. Until a candidate is approved and commercialized, the company lacks recurring operating income to offset research spending or support internally funded growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
Minimal debt reduces solvency risk and avoids a substantial interest burden while Eledon funds clinical development. This gives management greater flexibility to allocate capital toward tegoprubart and may provide more room to pursue financing or partnerships without an already heavily leveraged balance sheet.
Read all positive factors
Eledon Pharmaceuticals (ELDN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$201.53M
Dividend YieldN/A
Average Volume (3M)887.51K
Price to Earnings (P/E)―
Beta (1Y)1.49
Revenue GrowthN/A
EPS Growth-1475.42%
CountryUS
Employees33
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.99
Shares Outstanding81,261,154
10 Day Avg. Volume732,123
30 Day Avg. Volume887,507
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-1.98
Enterprise Value/Market Cap1.98
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.92
Forecast
1Y Price Target
$9.50Price Target Upside186.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)N/A
Eledon Pharmaceuticals Business Overview & Revenue Model
Company Description
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantat...
How the Company Makes Money
As a clinical-stage biotechnology company, Eledon Pharmaceuticals has not historically relied on recurring product sales and its ability to generate operating revenue from commercialized drugs is null. Instead, its funding model has primarily been...
Eledon Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -80.92M | -45.27M | -35.39M | -116.16M | -39.41M | -36.66M |
| Net Income | -98.56M | -45.62M | -36.18M | -116.54M | -87.97M | -34.51M |
Balance Sheet | ||||||
| Total Assets | 126.09M | 169.01M | 177.41M | 89.07M | 92.79M | 170.55M |
| Cash, Cash Equivalents and Short-Term Investments | 88.76M | 133.34M | 140.18M | 51.10M | 56.41M | 84.83M |
| Total Debt | 467.00K | 641.00K | 954.00K | 383.00K | 746.00K | 769.00K |
| Total Liabilities | 54.06M | 87.92M | 59.27M | 81.86M | 8.61M | 6.55M |
| Stockholders Equity | 72.03M | 81.08M | 118.14M | 7.21M | 84.18M | 164.00M |
Cash Flow | ||||||
| Free Cash Flow | -73.86M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Operating Cash Flow | -73.86M | -62.34M | -47.27M | -39.53M | -28.42M | -28.91M |
| Investing Cash Flow | 21.14M | 10.79M | -70.31M | -45.29M | 0.00 | 0.00 |
| Financing Cash Flow | 53.78M | 53.81M | 133.52M | 33.02M | 0.00 | -449.00K |
Eledon Pharmaceuticals Technical Analysis
Negative
3.32
Price Trends
3.04
Negative
3.40
Negative
3.05
Negative
Market Momentum
-0.17
Negative
35.08
Neutral
24.34
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ELDN, the sentiment is Negative. The current price of 3.32 is above the 20-day moving average (MA) of 2.60, above the 50-day MA of 3.04, and above the 200-day MA of 3.05, indicating a bearish trend. The MACD of -0.17 indicates Negative momentum. The RSI at 35.08 is Neutral, neither overbought nor oversold. The STOCH value of 24.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ELDN.
Eledon Pharmaceuticals Risk Analysis
Eledon Pharmaceuticals disclosed 39 risk factors in its most recent earnings report. Eledon Pharmaceuticals reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eledon Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $271.14M | 0.83 | -6.74% | ― | -100.00% | 95.16% | |
52 Neutral | $225.08M | -3.68 | -68.44% | ― | 19.49% | -4.53% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $261.21M | -2.08 | -65.08% | ― | -23.36% | 27.52% | |
47 Neutral | $271.58M | -1.42 | -33.22% | ― | 215.59% | 22.48% | |
46 Neutral | $238.24M | -17.00 | -31.27% | ― | 1.32% | 59.94% | |
42 Neutral | $201.53M | -2.51 | -136.45% | ― | ― | -1475.42% |
* Healthcare Sector Average
ELDN
Eledon Pharmaceuticals
2.48
-0.24
-8.82%
MGNX
MacroGenics
3.74
2.10
128.05%
FATE
Fate Therapeutics
2.18
0.79
56.83%
PRQR
ProQR
1.63
-0.66
-28.82%
BCYC
Bicycle Therapeutics
3.89
-4.23
-52.09%
SABS
SAB Biotherapeutics
2.98
0.67
29.00%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.